Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant.
Oral inhalation of anticancer drugs or drug delivery system is a novel therapeutic approach in the treatment of lung cancer and requires formulations which are sufficiently stabile during nebulisation and subsequent interaction with the surfactant lining of the lungs. In this study, we assessed the stability of plain and PEGylated transferrin-conjugated liposomes after nebulisation using two different nebulisers (i.e., air-jet and ultrasonic type). Furthermore, the integrity of the liposomal membranes was assessed after incubation in commercial lung surfactant solutions (Alveofact). All liposomal formulations showed no significant changes in their size after nebulisation, independent of the type of nebuliser or the liposomal formulation, respectively. However, PEGylation was of advantage when it came to interactions between liposomes and the surfactant lining of the lungs. PEGylated liposomes were significantly more stable and retained > 80% of their drug load over 48 h, which is more than sufficient time for the drug carriers to be taken up by transferrin receptor over-expressing cancer cells in the lung. In conclusion, PEGylated and plain Tf-conjugated liposomes are stable enough to undergo nebulisation in the course of an inhalational therapy, but PEG-stabilisation results in a higher degree of membrane integrity in lung surfactant.
Anabousi
Samah
S
Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken, Germany.
Kleemann
Elke
E
Bakowsky
Udo
U
Kissel
Thomas
T
Schmehl
Thomas
T
Gessler
Tobias
T
Seeger
Werner
W
Lehr
Claus-Michael
CM
Ehrhardt
Carsten
C
D004337:Drug Carriers / Q000737:chemistry*; D004355:Drug Stability; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D008422:Materials Testing; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D010743:Phospholipids / Q000008:administration & dosage / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000737:chemistry
D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D010743:Phospholipids; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation; D011092:Polyethylene Glycols